Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 7/20 | 0.87 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.87 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.87 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873567 | 0.87 | CYP17A1 (0.65) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| SCHEMBL61924 | 0.85 | GFER (0.70) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| 4,4'-Methylenedianiline SCHEMBL2851475 | 0.84 | CYP3A4 (0.88) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| 4,4'-Methylenedianiline SCHEMBL6907269 | 0.84 | CYP3A4 (0.88) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| SCHEMBL3482770 | 0.84 | CYP3A4 (1.00) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| 4,4'-Methylenedianiline SCHEMBL28001 | 0.84 | CYP3A4 (1.00) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| SCHEMBL6362775 | 0.84 | CYP3A4 (1.00) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| SCHEMBL8094139 | 0.84 | CYP3A4 (1.00) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| SCHEMBL1304762 | 0.84 | CYP3A4 (1.00) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| SCHEMBL721736 | 0.84 | CYP17A1 (0.61) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
| US-20240279215-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED | 2024-08-22 | — | — | US | disclosed |
| EP-4384520-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| CN-118076607-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| US-20240116857-A1 | QUATERNARY AMMONIUM COMPOUNDS AS ANTIMICROBIALS | SAINT LOUIS UNIVERSITY (US) | 2024-04-11 | — | — | US | disclosed |
| CN-117843569-A | Isoquinoline acrylamide CDK8 inhibitor, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2024-04-09 | — | — | CN | disclosed |
| WO-2024028169-A1 | NOVEL SPECIFICALLY SUBSTITUTED THIOPHENOLIC COMPOUNDS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-02-08 | — | — | WO | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023017442-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| EP-0763535-A1 | Piperidinylmethyloxazolidin-2-one derivatives, their preparation and their use as pharmacological active CNS compounds | MERCK PATENT GmbH (DE) | 1997-03-19 | — | — | EP | disclosed |
| EP-0691966-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5455252-A | Antiinflammatory agent, immunosuppressant, antiallergen, skin disorders, bronchodilator, analgesic | SYNTEX (U.S.A.) INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1994022852-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0089394-A1 | 1-H-Indole-2,3-dione derivatives and preparation thereof | STERLING DRUG INC. (US) | 1983-09-28 | — | — | EP | disclosed |
| EP-0056260-A1 | Pyridinyl-substituted-benz imidazole derivatives and preparation | STERLING DRUG INC. (US) | 1982-07-21 | — | — | EP | disclosed |
| EP-0055453-A2 | 5-(Pyridinyl)-benzimidazole derivatives and preparation | STERLING DRUG INC. (US) | 1982-07-07 | — | — | EP | disclosed |
| US-4335132-A | 5-(Py-Y)-1H-benzimidazol-2-ols and 5-(Py-Y-)-1H-benzimidazole-2-thiols | STERLING DRUG, INC. (US) | 1982-06-15 | — | — | US | disclosed |
| US-4331671-A | 5-(Pyridinyl)-1H-benzimidazoles and 1-hydroxy-6-(pyridinyl)-1H-benzimidazoles and their cardiotonic use | STERLING DRUG INC. (US) | 1982-05-25 | — | — | US | disclosed |
| US-4322533-A | CARDIOTONIC, BRONCHODILATOR, AND ANTICHLOLINERGIC AGENTS; ANTIMISTAMINES; ANTIALLERGENS | STERLING DRUG INC. | 1982-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | CYP17A1 3048/4885CYP11B1 966/4885CYP11B2 693/4885 |
| US-20240279215-A1 | NAMPT MODULATORS | NAMPT, SIRT1, NNT | CYP17A1 1443/4885CYP11B1 210/4885CYP11B2 305/4885 |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CYP17A1 2682/4885CYP11B1 3615/4885CYP11B2 3804/4885 |
| US-20240116857-A1 | QUATERNARY AMMONIUM COMPOUNDS AS ANTIMICROBIALS | ABCC1, ARG1, SLC11A2 | CYP17A1 4610/4885CYP11B1 2556/4885CYP11B2 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.